Surgery Branch
Tumor Immunology Section
Investigator

National Cancer Institute
9000 Rockville Pike
Building 10, Room 3-5930, MSC 1201
Bethesda, MD 20892

Phone: 301-435-8606
Fax: 301-435-5167
kammulau@mail.nih.gov

Dr. Kammula received his B.A. from Johns Hopkins University and his M.D. from the University of Maryland. He completed his general surgery residency at the University of Chicago Hospitals and fellowships in surgical oncology in the Surgery Branch of the National Cancer Institute and at Memorial Sloan-Kettering Cancer Center in New York. Dr. Kammula's research is focused on studies of tumor immunology and the development of effective immunotherapies for the treatment of patients with cancer. His clinical interests are in the management of cutaneous and ocular melanoma and of malignancies of the liver, pancreas, and gastrointestinal tract.

Dr. Kammula's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with melanoma or digestive/gastrointestinal cancers. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin NCI-13-C-0093, NCT01814046

Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets NCI-12-C-0175, NCT01658917

Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin NCI-12-C-0045, NCT01495572